Globeflex Capital L P Takes $2.54 Million Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Globeflex Capital initiated a $2.54 million position in Amneal Pharmaceuticals by purchasing 146,508 shares. Institutional investors collectively own 31.82% of the company.
• Amneal insiders sold 413,016 shares worth approximately $7.22 million over the past 90 days, including substantial sales by two executive vice presidents.
• Amneal reported quarterly EPS of $0.30, beating estimates of $0.24, while analysts maintain an overall “Buy” rating with an average price target of $17.67.

Globeflex Capital L P bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 146,508 shares of the company's stock, valued at approximately $2,536,000.

Several other institutional investors have also added to or reduced their stakes in the company. Westshore Wealth LLC bought a new position in Amneal Pharmaceuticals during the 3rd quarter worth $13,833,000. Morgan Stanley boosted its position in shares of Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company's stock valued at $60,708,000 after acquiring an additional 1,315,018 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company's stock valued at $32,405,000 after acquiring an additional 1,069,400 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Amneal Pharmaceuticals in the second quarter valued at about $17,573,000. Finally, Penn Capital Management Company LLC bought a new position in Amneal Pharmaceuticals during the fourth quarter worth about $12,655,000. 31.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares of the company's stock, valued at approximately $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the completion of the transaction, the executive vice president directly owned 253,390 shares of the company's stock, valued at $4,436,858.90. This trade represents a 36.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 413,016 shares of company stock worth $7,216,567 over the last 90 days. Insiders own 17.30% of the company's stock.

Amneal Pharmaceuticals Price Performance

Shares of AMRX opened at $17.91 on Monday. The firm has a 50 day simple moving average of $17.52 and a two-hundred day simple moving average of $14.74. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. Amneal Pharmaceuticals, Inc. has a one year low of $9.20 and a one year high of $19.26. The company has a market cap of $5.72 billion, a P/E ratio of 36.55 and a beta of 1.27.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AMRX. The Goldman Sachs Group reissued a "buy" rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. UBS Group lifted their price target on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Barclays boosted their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 20th. Weiss Ratings lowered Amneal Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of "Buy" and an average price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source